Brokerages expect DexCom, Inc. (NASDAQ:DXCM) to report sales of $217.84 million for the current fiscal quarter, Zacks reports. Six analysts have made estimates for DexCom’s earnings, with estimates ranging from $217.50 million to $218.16 million. DexCom posted sales of $171.20 million during the same quarter last year, which indicates a positive year-over-year growth rate of 27.2%. The business is expected to issue its next earnings results after the market closes on Tuesday, February 27th.

According to Zacks, analysts expect that DexCom will report full year sales of $217.84 million for the current year, with estimates ranging from $715.00 million to $725.00 million. For the next financial year, analysts expect that the company will post sales of $840.16 million per share, with estimates ranging from $833.80 million to $847.60 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover DexCom.

A number of research analysts recently issued reports on DXCM shares. BidaskClub downgraded DexCom from a “strong-buy” rating to a “buy” rating in a report on Friday, December 22nd. Jefferies Group boosted their price target on DexCom from $58.00 to $70.00 and gave the company a “buy” rating in a report on Friday, December 22nd. TheStreet downgraded DexCom from a “c-” rating to a “d+” rating in a report on Wednesday, October 25th. Barclays reduced their price target on DexCom from $60.00 to $57.00 and set an “equal weight” rating on the stock in a report on Thursday, November 2nd. Finally, Northland Securities restated a “hold” rating and set a $50.00 price target on shares of DexCom in a report on Thursday, November 2nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $68.50.

Shares of DexCom (NASDAQ DXCM) traded down $1.09 during trading hours on Friday, reaching $56.19. The company had a trading volume of 776,056 shares, compared to its average volume of 1,517,602. DexCom has a 52 week low of $42.62 and a 52 week high of $86.32. The stock has a market cap of $4,880.00, a P/E ratio of -98.58 and a beta of 0.21. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86.

In other DexCom news, EVP Andrew K. Balo sold 3,245 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $61.23, for a total transaction of $198,691.35. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $55.00, for a total value of $660,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 48,140 shares of company stock worth $2,743,281 in the last quarter. Company insiders own 1.70% of the company’s stock.

Several institutional investors have recently bought and sold shares of DXCM. JPMorgan Chase & Co. grew its stake in shares of DexCom by 143.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,358,507 shares of the medical device company’s stock worth $107,170,000 after buying an additional 7,738,678 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of DexCom by 101,699.8% in the 2nd quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock worth $499,522,000 after buying an additional 6,822,023 shares during the last quarter. Brown Advisory Inc. grew its stake in shares of DexCom by 57.2% in the 3rd quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock worth $203,798,000 after buying an additional 1,515,134 shares during the last quarter. Frontier Capital Management Co. LLC grew its stake in shares of DexCom by 85.0% in the 3rd quarter. Frontier Capital Management Co. LLC now owns 848,670 shares of the medical device company’s stock worth $41,521,000 after buying an additional 389,947 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of DexCom by 1,190.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 333,978 shares of the medical device company’s stock worth $16,338,000 after buying an additional 308,098 shares during the last quarter.

ILLEGAL ACTIVITY NOTICE: This article was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/dexcom-inc-dxcm-expected-to-post-quarterly-sales-of-217-84-million/1846674.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.